Low dose of carglumic acid for treatment of hyperammonemia due to N-acetylglutamate synthase deficiency.

نویسندگان

  • Ertugrul Kiykim
  • Tanyel Zubarioglu
چکیده

Nutritional deficiency of folate and its further depletion with chemotherapy is common in children with ALL, especially in countries with high prevalence of malnutrition and lack of folate fortification [2]. Despite a documented higher infection-related deaths during induction, and interruption of maintenance chemotherapy in folate deficient children, the theoretical concern of increased relapse has prevented us from supplementing with folic acid. Developed countries with mandatory folate fortification have not encountered increased relapses in the post-fortification era; this is further supported by data from adults where routine folate use during chemotherapy helps in improving the chemotherapy tolerance without compromising efficacy [3].

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

New developments in the treatment of hyperammonemia: emerging use of carglumic acid

Hyperammonemia is a true neonatal emergency with high toxicity for the central nervous system and developmental delay. The causes of neonatal hyperammonemia are genetic defects of urea cycle enzymes, organic acidemias, lysinuric protein intolerance, hyperammonemia-hyperornithinemia- homocitrullinemia syndrome, transient hyperammonemia of the newborn, and congenital hyperinsulinism with hyperamm...

متن کامل

Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency

N-acetylglutamate synthase (NAGS) deficiency is a rare inborn error of metabolism affecting ammonia detoxification in the urea cycle. The product of NAGS is N-acetylglutamate which is the absolutely required allosteric activator of the first urea cycle enzyme carbamoylphosphate synthetase 1. In defects of NAGS, the urea cycle function can be severely affected resulting in fatal hyperammonemia i...

متن کامل

Hyperammonemic encephalopathy in an adenocarcinoma patient managed with carglumic acid.

Hyperammonemic encephalopathy (he) is a rare complication of malignancy and chemotherapy. Although the cause of he is unclear, a functional arginine deficiency secondary to increased catabolism has been suggested as a possible mechanism. Either that deficiency or an undetermined metabolite could lead to inhibition of N-acetylglutamate synthase (nags), a urea cycle enzyme, resulting in hyperammo...

متن کامل

Title of Document : CHARACTERIZATION OF THE N - ACETYLGLUTAMATE SYNTHASE KNOCKOUT MOUSE , A NOVEL MODEL OF HYPERAMMONEMIA

Title of Document: CHARACTERIZATION OF THE NACETYLGLUTAMATE SYNTHASE KNOCKOUT MOUSE, A NOVEL MODEL OF HYPERAMMONEMIA. Emilee Senkevitch, PhD, 2012 Directed By: Professor Mendel Tuchman, Department of Pediatrics, Children's National Medical Center, George Washington University Professor David Mosser, Department of Cell Biology and Molecular Genetics All knockout mouse models of urea cycle disord...

متن کامل

N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment

The conversion of ammonia into urea by the human liver requires the coordinated function of the 6 enzymes and 2 transporters of the urea cycle. The initial and rate-limiting enzyme of the urea cycle, carbamylphosphate synthetase 1 (CPS1), requires an allosteric activator, N-acetylglutamate (NAG). The formation of this unique cofactor from glutamate and acetyl Coenzyme-A is catalyzed by N-acetyl...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Indian pediatrics

دوره 51 9  شماره 

صفحات  -

تاریخ انتشار 2014